Durable response achieved using Pazopanib for germ tumor cells: A case report

Takezawa,Yuta; Yaegashi,Hiroshi; Iijima,Masashi; Kawaguchi,Shohei; Nohara,Takahiro; Shigehara,Kazuyoshi; Izumi,Kouji; Kadono,Yoshihumi; Ikeda,Hiroko; Mizokami,Atsushi

doi:10.3892/mco.2021.2210

March-2021 Volume 14 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2021 Volume 14 Issue 3

Full Size Image

Case Report

Durable response achieved using Pazopanib for germ tumor cells: A case report

Authors:
- Yuta Takezawa
- Hiroshi Yaegashi
- Masashi Iijima
- Shohei Kawaguchi
- Takahiro Nohara
- Kazuyoshi Shigehara
- Kouji Izumi
- Yoshihumi Kadono
- Hiroko Ikeda
- Atsushi Mizokami
View Affiliations / Copyright

Affiliations: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920‑8641, Japan, Department of Diagnostic Pathology, Kanazawa University Hospital, Kanazawa, Ishikawa 920‑8641, Japan
Article Number: 48
|
Published online on: January 19, 2021

https://doi.org/10.3892/mco.2021.2210
Expand metrics +

Abstract

Germ cell tumors with somatic‑type malignancy (GCTSTM) are rare, and patients with GCTSTM have extremely poor prognoses with a median survival of nine months. Somatic‑type malignancy, which are mainly sarcomas, usually exhibit chemoresistance. The recommended therapy for GCTSTM is radical resection; however, Pazopanib, which is a multityrosine kinase inhibitor, has indicated therapeutic effects for some soft tissue sarcoma components. The current study reports the case of a 21‑year‑old Asian man who presented with GCTSTM after combined chemotherapy for a primary mediastinal germ cell tumor with multiple lung metastases. Despite the metastases, his disease was stable after continuous administration of Pazopanib for two years and then stopping the medication for four years. To the best of our knowledge, the current report is the first report of a durable response by Pazopanib for GCTSTM, which is a rare outcome.

View Figures

View References

1	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC (eds): World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. 1st edition. IARC Press, Lyon, 2004.
2	Motzer RJ, Amsterdam A, Prieto V, Sheinfeld J, Murty VV, Mazumdar M, Bosl GJ, Chaganti RS and Reuter VE: Teratoma with malignant transformation: Diverse malignant histologies arising in men with germ cell tumors. J Urol. 159:133–138. 1998.PubMed/NCBI View Article : Google Scholar
3	Malagón HD, Valdez AM, Moran CA and Suster S: Germ cell tumors with sarcomatous components: A clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol. 31:1356–1362. 2007.PubMed/NCBI View Article : Google Scholar
4	Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RS and Bosl GJ: Chemotherapy for teratoma with malignant transformation. J Clin Oncol. 21:4285–4291. 2003.PubMed/NCBI View Article : Google Scholar
5	Marina N, London WB, Frazier AL, Lauer S, Rescorla F, Cushing B, Malogolowkin MH, Castleberry RP, Womer RB and Olson T: Prognostic factors in children with extragonadal malignant germ cell tumors: A pediatric intergroup study. J Clin Oncol. 24:2544–2548. 2006.PubMed/NCBI View Article : Google Scholar
6	Michael H: Somatic neoplasms arising in germ cell tumors. Pathol Case Rev. 10:181–185. 2005.
7	Mikuz G and Colecchia M: Teratoma with somatic-type malignant components of the testis. A review and an update. Virchows Arch. 461:27–32. 2012.PubMed/NCBI View Article : Google Scholar
8	Arai K, Ohta S, Suzuki M and Suzuki H: Primary immature mediastinal teratoma in adulthood. Eur J Surg Oncol. 23:64–67. 1997.PubMed/NCBI View Article : Google Scholar
9	Kesler KA, Rieger KM, Ganjoo KN, Sharma M, Fineberg NS, Einhorn LH and Brown JW: Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery. J Thorac Cardiovasc Surg. 118:692–700. 1999.PubMed/NCBI View Article : Google Scholar
10	GlaxoSmithKline: Votrient Prescribing Information [cited Jun 1, 2020]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf. 2009.
11	Gril B, Palmieri D, Qian Y, Anwar T, Ileva L, Bernardo M, Choyke P, Liewehr DJ, Steinberg SM and Steeg PS: The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One. 6(e25625)2011.PubMed/NCBI View Article : Google Scholar
12	Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, et al: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 6:2012–2021. 2007.PubMed/NCBI View Article : Google Scholar
13	van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, et al: Pazopanib for metastatic soft tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
14	Yoon SS, Segal NH, Park PJ, Detwiller KY, Fernando NT, Ryeom SW, Brennan MF and Singer S: Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res. 135:282–290. 2006.PubMed/NCBI View Article : Google Scholar
15	Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Calareso G, Togliardi E, Crippa F, Pennati M, Zaffaroni N, Perrone F, et al: Pazopanib in advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, phase 2 Pazotest trial. Ann Oncol. 28:1346–1351. 2017.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Durable response achieved using Pazopanib for germ tumor cells: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles